ストックスクリーナーアプリを入手
9.72
2.91%
-0.25
前日終値:
$9.97
開ける：
$9.92
24時間の取引高:
107.25K
Relative Volume:
0.57
時価総額：
$484.87M
収益：
$62.02M
当期純損益:
$-45.65M
株価収益率:
0.8556
EPS:
11.36
ネットキャッシュフロー:
$-9.60M
1週間 パフォーマンス:
+1.15%
1か月 パフォーマンス:
+11.78%
6か月 パフォーマンス:
+6.14%
1年 パフォーマンス:
-5.84%
1日の値動き範囲:
$9.68
$9.97
1週間の範囲:
$9.25
$10.10
52週間の値動き範囲:
$7.44
$11.71
Theravance Biopharma Inc Stock (TBPH) Company Profile
名前
Theravance Biopharma Inc
セクター
電話
650-808-6000
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TBPH | 9.705 | 484.87M | 62.02M | -45.65M | -9.60M | 11.36 |
| VRTX | 448.94 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.42 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.19 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.82 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-15 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-08-25 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 開始されました | JP Morgan | Overweight |
| 2020-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 開始されました | Cowen | Outperform |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-06 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-29 | 再開されました | Piper Jaffray | Overweight |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 繰り返されました | Needham | Buy |
| 2016-12-21 | 開始されました | Needham | Buy |
| 2016-11-03 | 開始されました | Piper Jaffray | Overweight |
| 2016-10-12 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 開始されました | Guggenheim | Buy |
| 2016-06-20 | 繰り返されました | Leerink Partners | Outperform |
| 2016-05-12 | 開始されました | Leerink Partners | Outperform |
| 2016-05-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
すべてを表示
Theravance Biopharma Inc (TBPH) 最新ニュース
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Initiatives - GuruFocus.com
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma’s Third Quarter 2024 Financial Insights - TipRanks
Theravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For - Simply Wall St
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire
What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - Defense World
5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance
Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Theravance study shows YUPELRI improves COPD lung function - Investing.com
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan
Where are the Opportunities in (TBPH) - Stock Traders Daily
Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com
Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) 財務データ
収益
当期純利益
現金流量
EPS
Theravance Biopharma Inc (TBPH) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Aug 07 '24 |
Buy |
7.80 |
999,800 |
7,798,440 |
9,511,150 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jul 10 '24 |
Sale |
9.00 |
4,000 |
36,000 |
335,965 |
| Samaha Eli | 10% Owner |
May 01 '24 |
Buy |
8.75 |
1,499,124 |
13,117,335 |
8,511,350 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Feb 22 '24 |
Sale |
8.71 |
1,254 |
10,922 |
311,733 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):